G. Penna, “Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602”, AO, vol. 51, no. 7, pp. 944–947, Sep. 2012.